Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA

Author:

Celesti Fabrizio,Gatta Andrea,Shallak Mariam,Chiaravalli Anna Maria,Cerati Michele,Sessa Fausto,Accolla Roberto S.,Forlani Greta

Abstract

Glioblastoma is the most malignant tumor of the central nervous system. Current treatments based on surgery, chemotherapy, and radiotherapy, and more recently on selected immunological approaches, unfortunately produce dismal outcomes, and less than 2% of patients survive after 5 years. Thus, there is an urgent need for new therapeutic strategies. Here, we report unprecedented positive results in terms of protection from glioblastoma growth in an animal experimental system after vaccination with glioblastoma GL261 cells stably expressing the MHC class II transactivator CIITA. Mice injected with GL261-CIITA express de novo MHC class II molecules and reject or strongly retard tumor growth as a consequence of rapid infiltration with CD4+ and CD8+ T cells. Importantly, mice vaccinated with GL261-CIITA cells by injection in the right brain hemisphere strongly reject parental GL261 tumors injected in the opposite brain hemisphere, indicating not only the acquisition of anti-tumor immune memory but also the capacity of immune T cells to migrate within the brain, overcoming the blood–brain barrier. GL261-CIITA cells are a potent anti-glioblastoma vaccine, stimulating a protective adaptive anti-tumor immune response in vivo as a consequence of CIITA-driven MHC class II expression and consequent acquisition of surrogate antigen-presenting function toward tumor-specific CD4+ Th cells. This unprecedented approach for glioblastoma demonstrates the feasibility of novel immunotherapeutic strategies for potential application in the clinical setting.

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference56 articles.

1. Cancers of the brain and CNS: Global patterns and trends in incidence;Miranda-Filho;Neuro Oncol,2017

2. Current concepts and management of glioblastoma;Preusser;Ann Neurol,2011

3. Surveillance, epidemiology, and end results: Cancer stat facts: Brain and other nervous system cancer2019

4. Hansson e: Astrocyte-endothelial interactions at the blood-brain barrier;Abbott;Nat Rev Neurosci,2006

5. Blood–brain barrier breakdown in septic encephalopathy and brain tumours*;Davies;J Anat,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3